5 Drugmakers Battle Over the $10 Billion Hemophilia Market

5 Drugmakers Battle Over the $10 Billion Hemophilia Market


Will Bioverativ be able to fend off these deep-pocketed foes? In the past, hemophilia patients have relied upon factor replacement therapies that need to be taken as often as every other day. However, that's changing because Eloctate and Alprolix use a new approach that allows them to bind to a recirculating protein called Fc so that they remain in the bloodstream longer.



from Biotech News